Log in

International Foundation for Patient Blood Management (IFPBM)

Resources

Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia.

This content is restricted to subscribers. If you are already a subscriber, please log in.

Login
Subscribe